Identifying Clinically Meaningful Endpoints to Accelerate Retinal Disease Trials
Time: 1:00 pm
day: Pre-Conference Workshop Day
Details:
With a lack of clinical endpoints that are relevant to both regulatory agencies, this workshop will explore the most clinically relevant biomarkers and endpoints that can drive progress in retinal disease therapies. Participants will gain insights into the latest technologies, challenges, and innovations for identifying meaningful endpoints in clinical trials.
This workshop will:
- Evaluate the balance between the cost and clinical relevance of advanced imaging techniques and their integration with clinical endpoints
- Analyze the potential for AI algorithms to segment and quantify retinal disease features that correlate with clinically meaningful improvements
- Discuss the utility of imaging biomarkers for surrogate endpoints in accelerated approval pathways
- Invest the relationship between structural markers and functional tests for better outcome prediction
- Explore the role of fluorescence lifetime imaging and other emerging tools for predicting disease progression and differentiating stages of geographic atrophy
- Assess how imaging endpoints may vary between early and late-stage diseases and their potential for mapping structural changes to functional tests
